Couture R, Kérouac R
Br J Pharmacol. 1987 Jun;91(2):265-73. doi: 10.1111/j.1476-5381.1987.tb10281.x.
The effect of mammalian tachykinins on plasma protein extravasation was assessed in the rat dorsal skin. Substance P (SP), neurokinin A (NKA) and neurokinin B (NKB) increased vascular permeability in a dose-related manner with a threshold dose of about 0.07 pmol in sodium pentobarbitone-anaesthetized animals. Plasma protein extravasation induced by the tachykinins was 100-500 times less in magnitude in animals anaesthetized with urethane. Plasma protein extravasation induced by SP (66 pmol) was significantly reduced (63%; P less than 0.001) by atropine (a muscarinic inhibitor) while that induced by NKA or NKB was unaffected by the inhibitor suggesting that a cholinergic component might only be involved in the vascular permeability elicited by SP. The rank order of potency for the tachykinins on plasma protein extravasation was: NKB greater than SP greater than NKA (in absence of atropine) and NKB greater than NKA greater than SP (in presence of atropine), suggesting that this vascular response is mediated by a SP-E receptor type. The amplitudes of the plasma protein extravasation induced by NKB and its hydrophilic analogue [Arg degrees]NKB were similar, indicating that the lipophilic features of the native peptide cannot account for its potent biological activity. Plasma protein extravasation was enhanced by the SP analogue [D-Pro4,Lys6,D-Trp7,9,10,Phe11]SP (4-11), thus showing the limitation of such SP analogues (antagonists) for characterizing the tachykinin receptors involved in vascular permeability.
在大鼠背部皮肤中评估了哺乳动物速激肽对血浆蛋白外渗的影响。在戊巴比妥钠麻醉的动物中,P物质(SP)、神经激肽A(NKA)和神经激肽B(NKB)以剂量相关的方式增加血管通透性,阈剂量约为0.07 pmol。在氨基甲酸乙酯麻醉的动物中,速激肽诱导的血浆蛋白外渗量小100 - 500倍。SP(66 pmol)诱导的血浆蛋白外渗被阿托品(一种毒蕈碱抑制剂)显著降低(63%;P小于0.001),而NKA或NKB诱导的血浆蛋白外渗不受该抑制剂影响,这表明胆碱能成分可能仅参与SP引起的血管通透性。速激肽对血浆蛋白外渗的效力排序为:NKB>SP>NKA(无阿托品时)和NKB>NKA>SP(有阿托品时),表明这种血管反应是由SP-E受体类型介导的。NKB及其亲水性类似物[精氨酸缺失]NKB诱导的血浆蛋白外渗幅度相似,表明天然肽的亲脂性特征不能解释其强大的生物活性。SP类似物[D-脯氨酸4,赖氨酸6,D-色氨酸7,9,10,苯丙氨酸11]SP(4 - 11)增强了血浆蛋白外渗,因此显示了此类SP类似物(拮抗剂)在表征参与血管通透性的速激肽受体方面的局限性。